Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02891408 · ClinicalTrials.gov registry record · Phase 1
Study to Evaluate the Pharmacokinetics of Firsocostat or Fenofibrate in Adults With Normal and Impaired Hepatic Function
A Phase 1 study, sponsored by Gilead Sciences.
- Completed
- Registry status
- Phase 1
- Development phase
- 74
- Enrollment target
NCT02891408 is a Phase 1 study that has completed, run by Gilead Sciences. The registered enrollment target is 74 participants.
The verdict
NCT02891408, a Phase 1 study, has completed, sponsored by Gilead Sciences.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 74 participants
- Enrollment target
Study Summary
The primary objectives of this study are to evaluate the single-dose pharmacokinetics (PK) of firsocostat in adults with normal hepatic function, and mild, moderate, or severe hepatic impairment and to evaluate the single-dose PK of fenofibrate in adults with normal hepatic function and mild hepatic impairment.
Interventions
- DRUG Fenofibrate
- DRUG Firsocostat
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 74 participants |
| Start Date | 2016-09-23 |
| Est. Completion | 2019-05-13 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02891408
The ClinicalTrials.gov registry entry for NCT02891408 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 74 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Gilead Sciences, which has 504 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Fenofibrate is the first listed.
NCT02891408 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02891408 about?
NCT02891408 is a clinical study titled "Study to Evaluate the Pharmacokinetics of Firsocostat or Fenofibrate in Adults With Normal and Impaired Hepatic Function". The primary objectives of this study are to evaluate the single-dose pharmacokinetics (PK) of firsocostat in adults with normal hepatic function, and mild, moderate, or severe hepatic impairment and to evaluate the single-dose PK of fenofibrate in adults with normal hepatic function and mild hepatic...
What is the current status of trial NCT02891408?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 74 participants. The study started on 2016-09-23. Estimated completion is 2019-05-13.
What interventions are being tested in trial NCT02891408?
The interventions under investigation include: Fenofibrate (DRUG), Firsocostat (DRUG).
Who is sponsoring clinical trial NCT02891408?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.